



## **Dr. Christina Winter**

(awarded in Vienna, 2007)

In 1993, Christina Winter (MD) joined Glaxo's clinical safety and pharmacovigilance department as a drug safety physician. One of her duties was to maintain the in-house medical terminology which was more specific than WHOART or COSTART. In 1994, she joined a working party at the MCA (now the MHRA) to review the regulator's ADROIT dictionary. This led to MEDDRA (Medical Dictionary for Drug Regulatory Affairs) that was subsequently adopted by ICH as MedDRA (Medical Dictionary for Regulatory Activities). Christina was one of the EFPIA

representatives in the ICH M1 (MedDRA) working group and continues to be actively involved with MedDRA.

She is a member of the EFPIA MedDRA Topic Group, the European informal MedDRA user group, the CIOMS working group for Standardised MedDRA Queries (SMQ) and co-rapporteur of the ICH MedDRA Points to Consider working group. Christina has also represented EFPIA in the MedDRA Management Board since 2001.

Daily activities within GlaxoSmithKline include advising on MedDRA applications for clinical safety and pharmacovigilance and liaison with the GSK Dictionary team in data management.

Prior to joining the pharmaceutical industry, Christina qualified in medicine and also completed a thesis in applied physiology (Trinity College, Dublin, Eire). She was subsequently a clinical lecturer in Cardiovascular studies, University of Leeds (UK), with a variety of academic/clinical roles including being an investigator in heart failure clinical trials.